HRG and FETUB antisense RNA 1 (HRG-AS1)

HRG and FETUB antisense RNA 1 (HRG-AS1, also known as RP11-573D15.8) is a long non-coding RNA transcribed antisense to HRG and FETUB loci on chromosome 3[1]. It has been shown to regulate proliferation and migration in breast cancer cells; its silencing reduces these malignant phenotypes, indicating an oncogenic role[2]. Expression levels of HRG-AS1 can serve as a negative prognostic biomarker in breast cancer[2]. Additionally, in HIV infection, HRG-AS1 expression is downregulated in elite controllers compared to HIV+ patients, suggesting a role in immune response and potential as a diagnostic biomarker[4]. Mechanistically, HRG-AS1 participates in RNA–RNA and ceRNA networks, potentially modulating important oncogenic and immune-regulatory pathways through interaction with miRNAs and mRNAs such as AKT1, FOXO1, and MAPK3[2][4]. No direct interactions with drugs or evidence for being a classical therapeutic target (receptor, enzyme, etc.) are known.

Other names

RP11-573D15.8ENSG00000197099

Acts via an RNA–RNA interaction mechanism (as part of competing endogenous RNA/ceRNA networks) to regulate other lncRNAs and influence downstream gene expression miRNA sponge activity affecting gene expression (notably mediated by miRNA MIR6820-001 for some pathways in cancer)